Docetaxel +/- AZD6244 in Melanoma - A double blind randomised phase 2 trial of docetaxel with or without AZD6244 in wt BRAF advanced melanoma.

Trial Profile

Docetaxel +/- AZD6244 in Melanoma - A double blind randomised phase 2 trial of docetaxel with or without AZD6244 in wt BRAF advanced melanoma.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 29 Jun 2016

At a glance

  • Drugs Selumetinib (Primary) ; Docetaxel
  • Indications Malignant melanoma
  • Focus Registrational; Therapeutic Use
  • Acronyms DOC-MEK
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 21 Jun 2016 Planned End Date changed from 1 Oct 2015 to 1 Jun 2017.
    • 04 Jun 2013 Primary endpoint 'Progression-free-survival-rate' has not been met, according to the 49th Annual Meeting of the American Society of Clinical Oncology abstract.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top